We just continue slogging through that swamp of lots of good evidence but no gold standard proof:
/www.ncbi.nlm.nih.gov/pubmed/24402990Somebody said...
Vitamin D and prostate cancer survival in veterans.
Der T1, Bailey BA2, Youssef D1, Manning T3, Grant WB4, Peiris AN1.
Author information
1
Department of Internal Medicine, East Tennessee State University, P.O. Box 70622, Johnson City, TN 37614.
2
Department Family Medicine, East Tennessee State University, P.O. Box 70621, Johnson City, TN 37614.
3
Mountain Home VAMC, Mountain Home, TN 37684.
4
Sunlight, Nutrition and Health Research Center, P.O. Box 641603, San Francisco, CA 94164-1603.
Abstract
Prostate cancer remains the second most commonly diagnosed cancer among the male population worldwide. Vitamin D deficiency has been linked to prostate cancer and its aggressiveness. Herein, we initiated a retrospective study to evaluate vitamin D status and monitoring in veterans with prostate cancer, and to examine the potential link between vitamin D and survival status and length of survival in this population. We found that veterans who were initially vitamin D deficient were significantly less likely to survive than those who were not initially deficient, and that both initial and follow-up vitamin D deficiency were associated with decreased likelihood of survival after prostate cancer diagnosis. We recommend that vitamin D deficiency be replaced in veterans with prostate cancer.
/www.ncbi.nlm.nih.gov/pubmed/25207358Somebody said...
Adv Exp Med Biol. 2014;810:17-32.
Vitamin D and cancer: an overview on epidemiological studies.
Ordóñez Mena JM, Brenner H.
Abstract
In recent years, a rapidly increasing number of studies have investigated the relationship of vitamin D with total cancer and site-specific cancer obtaining diverse findings. In this chapter we provide an overview of epidemiological studies of vitamin D intake, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D serum levels and vitamin D associated polymorphisms in relation to total and site-specific cancer risk. Overall, epidemiological evidence for total cancer is inconclusive. However, a large number of studies support a relationship of vitamin D with colorectal cancer and to a lesser extent with breast cancer. Findings are inconsistent for other cancers including all other gastrointestinal cancers and prostate cancer. Different vitamin D associated polymorphisms were found to be significantly associated to colorectal, breast and prostate cancer risk.
/www.ncbi.nlm.nih.gov/pubmed/25085835Somebody said...
Format: Abstract
Send to
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1447-9. doi: 10.1158/1055-9965.EPI-14-0520.
Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial.
Schwartz GG1.
Author information
1
Departments of Cancer Biology, Urology, and Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina [email protected].
Abstract
The effects of blood levels of 25-hydroxyvitamin D (25-OHD) on the risk of total, low-, and high-grade prostate cancer were examined in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Prostate Cancer Prevention Trial (PCPT). In the SELECT study, plasma 25-OHD levels were associated with a linear decrease in prostate cancer risk for high-grade cancers in African American men and an apparent "U"-shaped effect in other men. The "U-shaped" curve may reflect detection bias. In the PCPT study, in which detection bias was minimized, serum 25-OHD levels were associated with a linear decrease in the risk of high-grade prostate cancers. The results from these large prevention trials support the hypothesis that circulating levels of 25-OHD decrease the risk of clinically relevant prostate cancers. .........................The hypothesis that vitamin D, or its major source, sunlight, inhibits prostate cancer has gone from a “dark horse” to a front-runner in the race to understand the epidemiology of prostate cancer. Clinically relevant prostate cancer preferentially afflicts the elderly, Blacks, and residents in northern latitudes (1). Conversely, the prevalence of subclinical prostate cancer (cancer detected in asymptomatic men) increases with age but does not vary by race or geography.
©2014 American Association for Cancer Research.
PMID:
25085835
DOI:
10.1158/1055-9965.EPI-14-0520
[Indexed for MEDLINE]
Free full text
clincancerres.aacrjournals.org/content/20/9/2241.longSomebody said...
Abstract
Clin Cancer Res. 2014 May 1;20(9):2241-3. doi: 10.1158/1078-0432.CCR-14-0369.
Vitamin D deficiency is associated with increased risk of prostate cancer for those with elevated prostate-specific antigen (PSA) level or abnormal digital rectal examination. Vitamin D deficiency is also associated with aggressive prostate cancer. Vitamin D level could be added as an additional factor to consider before ordering a biopsy. Clin Cancer Res; 20(9); 2241–3. ©2014 AACR.
See related article by Murphy et al., p. 2289
In this issue of Clinical Cancer Research, Murphy and colleagues associate vitamin D deficiency with increased risk of prostate cancer diagnosis on biopsy (1). Men in this study had their first prostate biopsy after a finding of an elevated or abnormal prostate-specific antigen (PSA) level or abnormal digital rectal examination. For African American (AA) men, serum 25-hydroxyvitamin D [25(OH)D] levels <20 ng/mL were significantly associated with prostate cancer, whereas for European American (EA) men, an insignificant increased risk of prostate cancer existed for serum 25(OH)D level <20 ng/mL. For both AA and EA men, serum 25(OH)D level <12 ng/mL was associated with a significant risk of stage ≥T2b and Gleason score ≥4 + 4. Thus, these findings add vitamin D status to the biomarkers for prostate cancer for those with other indications of prostate cancer.
This study offers further evidence that vitamin D deficiency is a risk factor for aggressive prostate cancer . Gilbert and colleagues associated low 25(OH)D levels with a 2-fold increased risk of advanced versus localized prostate cancer or high-grade versus low-grade prostate cancer (2). As with most observational studies (2), this study also found no correlation of serum 25(OH)D level with overall prostate cancer risk.
But sadly, we still have no
proof for some mysterious reason. So let each proceed as common sense, in consultation with your doctors, seems to dictate.
Post Edited (BillyBob@388) : 6/13/2017 10:07:15 PM (GMT-6)